XXXX : clinical course according to bone marrow cytology and cellularity.

@entity1 @entity7139 @entity417 @entity13832 @entity2150 @entity2590 @entity6130 @entity3052 @entity3800 @entity1503 @entity1778 @entity11596 @entity236 @entity2609
One hundred and one @entity1 with @entity13832 cytopenia were reviewed for morphological classification (using bone marrow, BM, imprints for cytology and Jamshidi biopsies for BM cellularity) and clinical course. Final diagnoses were: moderate @entity2150 ( @entity11596 ), @entity2590 ( @entity2590 ) and @entity3052 ( @entity3052 ). Ninety-two @entity1 received high dose @entity2609 (TE) as first treatment (starting dose = 7-10 mg/week i.m. for at least three months). Median survival was significantly longer in @entity11596 than in @entity2590 and in @entity3052 . Among @entity2590 @entity1 , those with primary acquired sideroblastic (AISA) and @entity13832 ( @entity13832 ) @entity417 had median survival similar to those with @entity11596 , but distinctly longer (p = 0.01) than @entity1 with @entity7139 ( @entity7139 ), @entity6130 (CMMoL). @entity3052 ( @entity3052 ) developed more rarely (p less than 0.02) in @entity11596 , AISA and @entity13832 than in @entity7139 , RAEBtr and CMMoL. Response to TE was seen in about two thirds of @entity11596 and in a half of @entity2590 and @entity3052 @entity1 . Among @entity2590 @entity1 , those with hypocellular BM developed @entity1778 less frequently, responded to @entity3800 more often and survived longer than those with normocellular and, especially, with hypercellular BM. These data indicate that the cytohistological classification of @entity1503 identifies essentially two groups with different clinical behaviour, one ( @entity11596 , AISA and @entity13832 ) having long life expectancy and a low probability of developing @entity3052 and the other ( @entity7139 , RAEBtr, CMMoL) with a short survival and relatively frequent @entity1778 . Bone @entity236 seems to be a favourable prognostic factor in @entity2590 . @entity1 with @entity1503 , especially those with a hypocellular BM, can be advantageously treated with @entity3800 .
